Birlasoft News, Corporate filings and Earnings/Conference Calls

Name: Latest research reports of Birlasoft Ltd. authored by ICICI Direct and published by - Trendlyne research reports.
Item: Birlasoft Ltd.
Rating: 3
Author: ICICI Direct

Keep track of all breaking news and updates on Birlasoft from all sources in a single place.

Birlasoft Ltd.

20 May 2026

319.35

-1.50%

Company Update

Birlasoft Ltd - 532400 - Compliances-Reg.24(A)-Annual Secretarial Compliance

BSE India

Annual Secretarial Compliance Report for the year ended March 31, 2026

pdf

Birlasoft Ltd.

13 May 2026

319.35

-1.50%

Earnings Call

Birlasoft Ltd - 532400 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript

BSE India

Transcript of Earnings Call held on May 6, 2026

pdf

Birlasoft Ltd.

08 May 2026, 06:07PM

319.35

-1.50%

KPIT co-founder and Chairman Ravi Pandit passes away at 76

Business Line

Pandit was a pioneering figure in India's automotive software and mobility ecosystem

Birlasoft Ltd. is trading below all available SMAs

Birlasoft Ltd.

08 May 2026

319.35

-1.50%

Birlasoft Ltd.

Hold: Birlasoft Ltd.

Target

ICICI Direct

Q4FY26 & FY26 Performance: Revenue stood at US$ 145.3 mn (1,348.6 crore), down 3.7% QoQ/ 5.1% YoY in CC terms. Reported EBITDA margin came at 18.5%, up ~30 bps QoQ. Reported PAT stood at 176 crore, up 46.7% QoQ. For FY26, revenue stood at US$ 597.5 mn, down 6% YoY (-6.5% YoY CC). Reported EBITDA...

Number of FII/FPI investors increased from 225 to 256 in Mar 2026 qtr.

Birlasoft Ltd.

07 May 2026

319.35

-1.50%

Company Update

Birlasoft Ltd - 532400 - Announcement under Regulation 30 (LODR)-Newspaper Publication

BSE India

Newspaper Publication - Financial Results

pdf

Birlasoft Ltd.

07 May 2026

319.35

-1.50%

Birlasoft: Q4FY26 Result Review

Buy: Birlasoft Ltd.

Recommendation Target

IDBI Capital

Birlasoft delivered a mixed FY26, with full-year revenues declining 6% in dollar terms to ~USD 598mn, weighed down by a soft demand environment, clientspecific headwinds in the life sciences/med-tech vertical, deliberate exits from low-margin contracts (~200bps revenue impact), and upfront productivity pass through on AI deals. Margin recovery was remarkable and EBITDA expanded 333bps YoY to 16.3% in FY26, reaching 18.5% in Q4, aided by cost rationalization, forex tailwinds (~170bps), and one-time provision reversals (~170bps). PAT for Q4 surged 47% QoQ to ~INR 1.76bn. Deal wins stayed above USD 200mn TCV for the second consecutive quarter. Management is doubling...